An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells

Caì, Yíngyún; Yú, Shuǐqìng; Chi, Xiangyang; Radoshitzky, Sheli R.; Kuhn, Jens H.; Berger, Edward A.

doi:10.1371/journal.pone.0245024

Cited by 4 publications

(8 citation statements)

References 56 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This hemorrhaging is how most health care workers, as well as family members, are infected. Quarantine and proper disposal have led to relatively smaller outbreaks occurring every few years since the most common route for infection is person to person through bodily fluids and direct contact [ 5 ].…”

Section: Zoonotic Diseasesmentioning

confidence: 99%

“…Ebola was 88% fatal to its victims [ 42 ]. Since the initial discovery of the Ebola virus and Ebola virus outbreak in 1976, six distinct strains have been identified, and there have been almost two dozen outbreaks across the globe [ 5 ]. Most of these outbreaks centered in South and Central Africa, with a few outbreaks appearing elsewhere ( Table 1 ).…”

Section: Zoonotic Diseasesmentioning

confidence: 99%

“…SARS-CoV-2, like all coronaviruses, attaches to host cell protein receptors through its spike glycoprotein, and this binding is mediated binding to HS on the surface of the host cells [ 5 , 6 ]. SARS-CoV-2 surface is decorated with envelope (E), membrane (M), and spike (S) proteins.…”

Section: Roles Of Gags In Pathogenesis Of Viral Zoonotic Diseasesmentioning

confidence: 99%

“…Cai and coworkers tested the possibility of using immunotoxins to prevent or reverse Ebola virus infection. These immunotoxins have been shown to bind to the GP-1, which, as stated above, inhibits the progression of Ebola virus infection in humanized cells as well as nonhuman primates [ 5 ]. One of the main symptoms of Ebola infection is the violent widespread hemorrhagic due to poor cell adhesion.…”

Section: Potential Prophylactic and Therapeutic Applications Of Gags In The Treatments Of Viral Zoonotic Diseasesmentioning

confidence: 99%

“… Structure of ( A ) Nipah from [ 103 ] ( B ) Hendra [ 104 ] ( C ) SARS-CoV-2 [ 105 ] ( D ) Ebola [ 106 ]. SARS, SARS-CoV-2, and MERS all require HS to act as a coreceptor in order to bind to host cells [ 5 , 6 , 48 ]. Many studies have been performed to investigate the inhibitory properties of HS against SARS and SARS-CoV-2.…”

Section: Figurementioning

confidence: 99%

See 4 more Smart Citations

Implications of Glycosaminoglycans on Viral Zoonotic Diseases

2021

View full text Add to dashboard Cite

Zoonotic diseases are infectious diseases that pass from animals to humans. These include diseases caused by viruses, bacteria, fungi, and parasites and can be transmitted through close contact or through an intermediate insect vector. Many of the world’s most problematic zoonotic diseases are viral diseases originating from animal spillovers. The Spanish influenza pandemic, Ebola outbreaks in Africa, and the current SARS-CoV-2 pandemic are thought to have started with humans interacting closely with infected animals. As the human population grows and encroaches on more and more natural habitats, these incidents will only increase in frequency. Because of this trend, new treatments and prevention strategies are being explored. Glycosaminoglycans (GAGs) are complex linear polysaccharides that are ubiquitously present on the surfaces of most human and animal cells. In many infectious diseases, the interactions between GAGs and zoonotic pathogens correspond to the first contact that results in the infection of host cells. In recent years, researchers have made progress in understanding the extraordinary roles of GAGs in the pathogenesis of zoonotic diseases, suggesting potential therapeutic avenues for using GAGs in the treatment of these diseases. This review examines the role of GAGs in the progression, prevention, and treatment of different zoonotic diseases caused by viruses.

show abstract

Section: Zoonotic Diseasesmentioning

confidence: 99%

Section: Zoonotic Diseasesmentioning

confidence: 99%

Section: Roles Of Gags In Pathogenesis Of Viral Zoonotic Diseasesmentioning

confidence: 99%

Section: Potential Prophylactic and Therapeutic Applications Of Gags In The Treatments Of Viral Zoonotic Diseasesmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Implications of Glycosaminoglycans on Viral Zoonotic Diseases

2021

View full text Add to dashboard Cite

show abstract

Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context

Ruschig

Marschall

2023

BioDrugs

View full text Add to dashboard Cite

Numerous toxins translocate to the cytosol in order to fulfil their function. This demonstrates the existence of routes for proteins from the extracellular space to the cytosol. Understanding these routes is relevant to multiple aspects related to therapeutic applications. These include the development of anti-toxin treatments, the potential use of toxins as shuttles for delivering macromolecular cargo to the cytosol or the use of drugs based on toxins. Compared with other strategies for delivery, such as chemicals as carriers for macromolecular delivery or physical methods like electroporation, toxin routes present paths into the cell that potentially cause less damage and can be specifically targeted. The efficiency of delivery via toxin routes is limited. However, low-delivery efficiencies can be entirely sufficient, if delivered cargoes possess an amplification effect or if very few molecules are sufficient for inducing the desired effects. This is known for example from RNA-based vaccines that have been developed during the coronavirus disease 2019 pandemic as well as for other approved RNA-based drugs, which elicited the desired effect despite their typically low delivery efficiencies. The different mechanisms by which toxins enter cells may have implications for their technological utility. We review the mechanistic principles of the translocation pathway of toxins from the extracellular space to the cytosol, the delivery efficiencies, and therapeutic strategies or applications that exploit toxin routes for intracellular delivery.

show abstract

Bacteria-derived chimeric toxins as potential anticancer agents

et al. 2022

View full text Add to dashboard Cite

Cancer is one of the major causes of death globally, requiring everlasting efforts to develop novel, specific, effective, and safe treatment strategies. Despite advances in recent years, chemotherapy, as the primary treatment for cancer, still faces limitations such as the lack of specificity, drug resistance, and treatment failure. Bacterial toxins have great potential to be used as anticancer agents and can boost the effectiveness of cancer chemotherapeutics. Bacterial toxins exert anticancer effects by affecting the cell cycle and apoptotic pathways and regulating tumorigenesis. Chimeric toxins, which are recombinant derivatives of bacterial toxins, have been developed to address the low specificity of their conventional peers. Through their targeting moieties, chimeric toxins can specifically and effectively detect and kill cancer cells. This review takes a comprehensive look at the anticancer properties of bacteria-derived toxins and discusses their potential applications as therapeutic options for integrative cancer treatment.

show abstract

An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells

Cited by 4 publications

References 56 publications

Implications of Glycosaminoglycans on Viral Zoonotic Diseases

Implications of Glycosaminoglycans on Viral Zoonotic Diseases

Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context

Bacteria-derived chimeric toxins as potential anticancer agents

Contact Info

Product

Resources

About